Uptake and distribution of fluorescein-labeled D2 dopamine receptor antisense oligodeoxynucleotide in mouse brain

Journal of Molecular Neuroscience

Volumn 7, Issue 1, 1996, Pages 13-28

  Zhang, Sui Po ^a   Zhou, Long Wu ^a   Morabito, Mark ^a   Lin, Rick C S ^a   Weiss, Benjamin ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Antisense oligonucleotide; D2 dopamine receptor; Phosphorothioate

Indexed keywords

DOPAMINE 2 RECEPTOR; FLUORESCEIN; FLUORESCEIN DERIVATIVE; NUCLEOTIDE; OLIGODEOXYRIBONUCLEOTIDE;

ANIMAL; ARTICLE; BRAIN; BRAIN LEVEL; BRAIN VENTRICLE; CYTOLOGY; EXTRACELLULAR SPACE; GENETICS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; METABOLISM; MOUSE; NERVE CELL; NERVE FIBER; NUCLEIC ACID PROBE;

ANIMALS; ANTISENSE ELEMENTS (GENETICS); BRAIN; BRAIN CHEMISTRY; CEREBRAL VENTRICLES; EXTRACELLULAR SPACE; FLUORESCEIN; FLUORESCEINS; INJECTIONS, INTRAVENTRICULAR; MALE; MICE; NERVE FIBERS; NEURONS; OLIGODEOXYRIBONUCLEOTIDES; RECEPTORS, DOPAMINE D2; THIONUCLEOTIDES;

EID: 0030093527     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02736845     Document Type: Article

References (12)

1. Adams J. U., Chen X. H., DeRiel J. K., Adler M. W., and Liu-Chen L.-Y. (1994) In vivo treatment with antisense oligodeoxynucleotide to kappa-opioid receptors inhibited kappa-agonist-induced analgesia in rats. Regul. Pept. 54, 1,2.
2. Agrawal S. and Iyer R. P. (1995) Modified oligonucleotides as therapeutic and diagnostic agents. Curr. Opin. Biotechnol. 6, 12-19.
3. Agrawal S., Temsamani J., Galbraith W., and Tang J. (1995) Pharmacokinetics of antisense oligonucleotides. Clin. Pharmacokinet. 28, 7-16.
4. Agrawal S., Temsamani J., and Tang J. Y. (1991) Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. USA 88, 7595-7599.
5. Beltinger C., Saragovi H. U., Smith R. M., LeSauteur L., Shah N., DeDionisio L., Christensen L., Raible A., Jarett L., and Gewirtz A. M. (1995) Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J. Clin. Invest. 95, 1814-1823.
6. Caceres A. and Kosik K. S. (1990) Inhibition of neurite polarity by tau antisense oligonucleotides in primary cerebellar neurons. Nature 343, 461-463.
7. Crooke S. T. (1992) Therapeutic applications of oligonucleotides. Ann. Rev. Pharmacol. Toxicol. 32, 329-376.
8. Goodale D. B., Jacobi A. G. M., Winkler J. D., and Weiss B. (1985) Rapid stereotaxic injections into mouse striatum using a plastic mold. Soc. Neurosci. 11, 772.
9. Iversen P. (1991) In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue. Anti-Cancer Drug Design 6, 531-538.
10. Iwanaga T. and Ferriola P. C. (1993) Cellular uptake of phosphorothioate oligodeoxynucleotides is negatively affected by cell density in a transformed rat tracheal epithelial cell line: implication for antisense approaches. Biochem. Biophys. Res. Commun. 191, 1152-1157.
11. Loke S. L., Stein C. A., Zhang X. H., Mori K., Nakanishi M., Subasinghe C., Cohen J. S., and Neckers L. M. (1989) Characterization of oligonucleotide transport into living cells. Proc. Natl. Acad. Sci. USA 86, 3474-3478.
12. Lu X.-M., Fischman A. J., Jyawook S. L., Hendricks K., Tompkins R. G., and Yarmush M. L. (1994) Antisense DNA delivery in vivo: liver targeting by receptor-mediated uptake. J. Nucl. Med. 35, 269-275.